Therapeutic Vulnerabilities of RAS Oncoproteins
RAS GTPases are prototypical members of the RAS protein superfamily and regulate a diverse range of cytoplasmic signaling networks. Commonly identified as oncogenes, mutations in RAS genes result in overactivation of pathways controlling cell differentiation and growth, oncogenesis and cancer, making them a key therapeutic target.
- Molecular biology of RAS
- RAS as a therapeutic target
- Identifying therapeutic vulnerabilities in RAS
- Therapy prospects for the future
About the Presenters
Adrienne Cox is Professor in the Department of Radiation Oncology, University of North Carolina at Chapel Hill, NC, USA. Her research investigates molecular mechanisms within cancer biology, particularly the protein function of Ras family oncogenes, and how these proteins control conversion of extracellular signals to intracellular responses.
The webinar is moderated by Judy O’Rourke, Labroots.